Cargando…
Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6773977/ https://www.ncbi.nlm.nih.gov/pubmed/31598491 http://dx.doi.org/10.3389/fonc.2019.00967 |
| _version_ | 1783456002958426112 |
|---|---|
| author | Pernas, Sonia Petit, Anna Climent, Fina Paré, Laia Perez-Martin, J. Ventura, Luz Bergamino, Milana Galván, Patricia Falo, Catalina Morilla, Idoia Fernandez-Ortega, Adela Stradella, Agostina Rey, Montse Garcia-Tejedor, Amparo Gil-Gil, Miguel Prat, Aleix |
| author_facet | Pernas, Sonia Petit, Anna Climent, Fina Paré, Laia Perez-Martin, J. Ventura, Luz Bergamino, Milana Galván, Patricia Falo, Catalina Morilla, Idoia Fernandez-Ortega, Adela Stradella, Agostina Rey, Montse Garcia-Tejedor, Amparo Gil-Gil, Miguel Prat, Aleix |
| author_sort | Pernas, Sonia |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6773977 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | Frontiers Media S.A. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-67739772019-10-09 Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution Pernas, Sonia Petit, Anna Climent, Fina Paré, Laia Perez-Martin, J. Ventura, Luz Bergamino, Milana Galván, Patricia Falo, Catalina Morilla, Idoia Fernandez-Ortega, Adela Stradella, Agostina Rey, Montse Garcia-Tejedor, Amparo Gil-Gil, Miguel Prat, Aleix Front Oncol Oncology Frontiers Media S.A. 2019-09-25 /pmc/articles/PMC6773977/ /pubmed/31598491 http://dx.doi.org/10.3389/fonc.2019.00967 Text en Copyright © 2019 Pernas, Petit, Climent, Paré, Perez-Martin, Ventura, Bergamino, Galván, Falo, Morilla, Fernandez-Ortega, Stradella, Rey, Garcia-Tejedor, Gil-Gil and Prat. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| spellingShingle | Oncology Pernas, Sonia Petit, Anna Climent, Fina Paré, Laia Perez-Martin, J. Ventura, Luz Bergamino, Milana Galván, Patricia Falo, Catalina Morilla, Idoia Fernandez-Ortega, Adela Stradella, Agostina Rey, Montse Garcia-Tejedor, Amparo Gil-Gil, Miguel Prat, Aleix Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution |
| title | Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution |
| title_full | Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution |
| title_fullStr | Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution |
| title_full_unstemmed | Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution |
| title_short | Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution |
| title_sort | corrigendum: pam50 subtypes in baseline and residual tumors following neoadjuvant trastuzumab-based chemotherapy in her2-positive breast cancer: a consecutive-series from a single institution |
| topic | Oncology |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6773977/ https://www.ncbi.nlm.nih.gov/pubmed/31598491 http://dx.doi.org/10.3389/fonc.2019.00967 |
| work_keys_str_mv | AT pernassonia corrigendumpam50subtypesinbaselineandresidualtumorsfollowingneoadjuvanttrastuzumabbasedchemotherapyinher2positivebreastcanceraconsecutiveseriesfromasingleinstitution AT petitanna corrigendumpam50subtypesinbaselineandresidualtumorsfollowingneoadjuvanttrastuzumabbasedchemotherapyinher2positivebreastcanceraconsecutiveseriesfromasingleinstitution AT climentfina corrigendumpam50subtypesinbaselineandresidualtumorsfollowingneoadjuvanttrastuzumabbasedchemotherapyinher2positivebreastcanceraconsecutiveseriesfromasingleinstitution AT parelaia corrigendumpam50subtypesinbaselineandresidualtumorsfollowingneoadjuvanttrastuzumabbasedchemotherapyinher2positivebreastcanceraconsecutiveseriesfromasingleinstitution AT perezmartinj corrigendumpam50subtypesinbaselineandresidualtumorsfollowingneoadjuvanttrastuzumabbasedchemotherapyinher2positivebreastcanceraconsecutiveseriesfromasingleinstitution AT venturaluz corrigendumpam50subtypesinbaselineandresidualtumorsfollowingneoadjuvanttrastuzumabbasedchemotherapyinher2positivebreastcanceraconsecutiveseriesfromasingleinstitution AT bergaminomilana corrigendumpam50subtypesinbaselineandresidualtumorsfollowingneoadjuvanttrastuzumabbasedchemotherapyinher2positivebreastcanceraconsecutiveseriesfromasingleinstitution AT galvanpatricia corrigendumpam50subtypesinbaselineandresidualtumorsfollowingneoadjuvanttrastuzumabbasedchemotherapyinher2positivebreastcanceraconsecutiveseriesfromasingleinstitution AT falocatalina corrigendumpam50subtypesinbaselineandresidualtumorsfollowingneoadjuvanttrastuzumabbasedchemotherapyinher2positivebreastcanceraconsecutiveseriesfromasingleinstitution AT morillaidoia corrigendumpam50subtypesinbaselineandresidualtumorsfollowingneoadjuvanttrastuzumabbasedchemotherapyinher2positivebreastcanceraconsecutiveseriesfromasingleinstitution AT fernandezortegaadela corrigendumpam50subtypesinbaselineandresidualtumorsfollowingneoadjuvanttrastuzumabbasedchemotherapyinher2positivebreastcanceraconsecutiveseriesfromasingleinstitution AT stradellaagostina corrigendumpam50subtypesinbaselineandresidualtumorsfollowingneoadjuvanttrastuzumabbasedchemotherapyinher2positivebreastcanceraconsecutiveseriesfromasingleinstitution AT reymontse corrigendumpam50subtypesinbaselineandresidualtumorsfollowingneoadjuvanttrastuzumabbasedchemotherapyinher2positivebreastcanceraconsecutiveseriesfromasingleinstitution AT garciatejedoramparo corrigendumpam50subtypesinbaselineandresidualtumorsfollowingneoadjuvanttrastuzumabbasedchemotherapyinher2positivebreastcanceraconsecutiveseriesfromasingleinstitution AT gilgilmiguel corrigendumpam50subtypesinbaselineandresidualtumorsfollowingneoadjuvanttrastuzumabbasedchemotherapyinher2positivebreastcanceraconsecutiveseriesfromasingleinstitution AT prataleix corrigendumpam50subtypesinbaselineandresidualtumorsfollowingneoadjuvanttrastuzumabbasedchemotherapyinher2positivebreastcanceraconsecutiveseriesfromasingleinstitution |